摘要
目的:探讨在宫颈患者诊断和分级中,癌基因E6/E7 mRNA定量检测与液基细胞学检查(thinprep cytologic test,TCT)联合应用的价值。方法:选择103例宫颈病变患者的临床资料,所有患者均给予癌基因E6/E7 mRNA定量检测与TCT检查,分析检查结果。结果:103例宫颈病变患者E6/E7 mRNA定量检测出98例阳性样本,阳性率95. 15%。炎性反应组16例,拷贝数(52. 12±43. 45); CINⅠ40例,拷贝数(156. 45±171. 34); CINⅡ22例,拷贝数(435. 45±345. 67); CINⅢ19例,拷贝数(567. 78±3603. 45);宫颈癌7例,拷贝数(789. 89±703. 23);分级中呈现递增趋势(P <0. 05)。结论:癌基因E6/E7 mRNA定量检测与TCT联合应用可作为宫颈病变患者分级及早期筛查的重要手段。
Objective： To explore the diagnostic value of combined detection of oncogene E6/E7 mRNA and Thinprep cytologic test（ TCT） in classification of patients with cervical lesions. Methods： The clinical data of 103 patients with cervical lesions were selected. They were given E6/E7 mRNA quantitative test and TCT. The results were analyzed. Results： In 103 cases of cervical lesions,98 cases were positive for E6/E7 mRNA,and the positive rate was 95. 15 %. There were 16 cases of inflammatory reaction,copy number（ 52. 12 ± 43. 45）,40 cases of CIN I,copy number（ 156. 45 ± 171. 34）,22 cases of CINⅡ,copy number（ 435. 45 ± 345. 67）,13 cases of CIN Ⅲ,copy number（ 567. 78 ± 3603. 45）,and7 cases of cervical cancer,copy number（ 789. 89 ± 703. 23）. There was an increasing trend in the classification（ P 〈 0. 05）. Conclusion： Quantitative detection of oncogene E6/E7 mRNA combined with TCT can be used as an important means for grading cervical lesions and screening early cervical lesions.
作者
邓蜓蜓
DENG Tingting(Department of Orthopedics Hospital,Southwest Guizhou Hospital of Traditional Chinese Medicine,Xingyi 562400,China)
出处
《包头医学院学报》
CAS
2018年第9期54-55,共2页
Journal of Baotou Medical College
